Translate Bio Names Daniella Beckman to Board of Directors
Wednesday, 04 October 2017 02:06
Oct. 4, 2017 11:30 UTC

Translate Bio Names Daniella Beckman to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Translate Bio, a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases, today announced the appointment of Daniella Beckman to its board of directors, effective immediately. Ms. Beckman will also serve as chairperson of the board’s audit committee.

“Daniella joins our board of directors at an exciting time for Translate Bio,” said Ronald Renaud, chief executive officer, Translate Bio. “Her financial and operational expertise will be vital as we continue to build the company and bring our first product candidate into the clinic for the treatment of cystic fibrosis in early 2018.”

“I am thrilled to join the Translate Bio board of directors at such a pivotal time for the organization,” said Ms. Beckman. “I look forward to supporting the Company and being a part of a dedicated team focused on developing innovative products for genetic diseases.”

Ms. Beckman has over 15 years of financial and operational experience working with private and publicly traded biotechnology companies. She currently provides consulting and interim chief financial officer services for early-stage biotechnology companies, which recently has included Tango Therapeutics and

Neon Therapeutics. With strategic and

Error. Page cannot be displayed. Please contact your service provider for more details. (8)

operational expertise, Ms. Beckman focuses on building financial infrastructure and
leading financial functions, including strategic financial planning. Previously, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. At Idenix, she oversaw finance, treasury, capital raises, investor relations and IT. Prior to the CFO role, Ms. Beckman also served as Idenix’s corporate controller. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Ms. Beckman holds a B.A. in business administration/accounting from Boston University. She is also a certified public accountant in Massachusetts.

Translate Bio’s lead development programs in cystic fibrosis and OTC deficiency are expected to begin Phase 1 clinical testing in early 2018 and mid-2018, respectively.

About Translate Bio
Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases including rare diseases of the liver, lung and central nervous system (CNS). For more information about the company, please visit www.translate.bio.

Contacts

Translate Bio
Maura Gavaghan, 857-242-7789
Corporate Communications
mgavaghan@translate.bio


Source: Translate Bio




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1